Cangrelor: A Review in Percutaneous Coronary Intervention

Drugs

Volumn 75, Issue 12, 2015, Pages 1425-1434

  Keating, Gillian M ^a  

^a Mairangi Bay   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CANGRELOR; CLOPIDOGREL; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR;

ARTICLE; BLEEDING; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPNEA; HUMAN; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; VOLUME OF DISTRIBUTION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CORONARY THROMBOSIS; DRUG EFFECTS; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MORTALITY; RISK FACTOR; THROMBOCYTE; TREATMENT OUTCOME;

ADENOSINE MONOPHOSPHATE; ADMINISTRATION, INTRAVENOUS; BLOOD PLATELETS; CORONARY THROMBOSIS; DRUG INTERACTIONS; HEMORRHAGE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RISK FACTORS; TREATMENT OUTCOME;

EID: 84939260117     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0445-3     Document Type: Article

References (52)

1. 12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30(16):1964-77.
2. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):e574-651.
3. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;127(4):529-55.
4. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-619.
5. Lhermusier T, Baker NC, Waksman R. Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor. Am J Cardiol. 2015;115(8):1154-61.
6. Waite LH, Phan YL, Spinler SA. Cangrelor: a novel intravenous antiplatelet agent with a questionable future. Pharmacotherapy. 2014;34(10):1061-76.
7. European Medicines Agency. Kengrexal (cangrelor): EU summary of product characteristics. 2015. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003773/WC500188098.pdf. Accessed 15 June 2015.
8. The Medicines Company. Kengreal™ (cangrelor) for injection, for intravenous use: US prescribing information. 2015. http://www.kengreal.com/pdfs/kengreal-us-prescribing-information.pdf. Accessed 24 June 2015.
9. i-dependent mechanism. PLoS One. 2012;7(12):e51037.
10. Akers WS, Oh JJ, Oestreich JH, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50(1):27-35.
11. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002;13(7):407-13.
12. 2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001;85(3):401-7.
13. 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006;151(3):689 e1-e10.
14. 2T receptor: a novel approach to antithrombotic therapy. J Med Chem. 1999;42(2):213-20.
15. i-independent increase in cAMP levels. J Biol Chem. 2009;284(24):16108-17.
16. Ferreiro J, Ueno M, Tello-Montoliu A, et al. Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. J Thromb Thrombolysis. 2013;35(2):155-64.
17. Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012;34(1):44-55.
18. Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121(4):527-34.
19. Green CL, Whellan DJ, Lambe L, et al. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. J Cardiovasc Pharmacol. 2013;62(5):466-78.
20. 12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost. 2008;6(7):1153-9.
21. Schneider DJ, Seecheran N, Raza SS, et al. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015;26(1):42-8.
22. Schneider DJ, Agarwal Z, Seecheran N, et al. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014;7(4):435-42.
23. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24):2318-29.
24. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(24):2330-41.
25. Leonardi S, Mahaffey KW, White HD, et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012;163(5):768-76.e2.
26. Leonardi S, Truffa AAM, Neely ML, et al. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013;99(17):1282-7.
27. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020-35.
28. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation. 2007;116(22):2634-53.
29. White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012;163(2):182-90 e4.
30. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303-13.
31. Généreux P, Stone GW, Harrington RA, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention). J Am Coll Cardiol. 2014;63(7):619-29.
32. White HD, Bhatt DL, Gibson CM, et al. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (a clinical trial comparing cangrelor to clopidogrel standard therapy in subjects who require percutaneous coronary intervention [PCI]). JACC Cardiovasc Interv. 2015;8(3):424-33.
33. O'Donoghue ML, Bhatt DL, Stone G, et al. The efficacy, safety, and net clinical benefit of cangrelor in women undergoing elective or urgent PCI: insights from the CHAMPION-PHOENIX trial [abstract no. 1139-083]. J Am Coll Cardiol. 2015;65(10 Suppl):A104.
34. Cavender M, Bhatt D, Stone G, et al. Cangrelor in elderly patients endergoing PCI: findings from CHAMPION-PHOENIX [abstract no. 2101-286 ]. J Am Coll Cardiol. 2015;65(10 Suppl):A1773.
35. Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382(9909):1981-92.
36. Angiolillo DJ, Bhatt DL, Steg PG, et al. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. J Thromb Thrombolysis. 2015;. doi: 10.1007/s11239-015-1233-3.
37. Bristol-Myers Squibb/Sanofi. Plavix (clopidogrel bisulfate) tablets: US prescribing information. 2013. http://www.bms.com/. Accessed 16 Apr 2015.
38. Eli Lilly and Company. Effient (prasugrel) tablets for oral use: US prescribing information. 2013. http://www.effient.com/. Accessed 16 Apr 2015.
39. ® (ticagrelor) tablets for oral use: US prescribing information. 2015. http://www.brilinta.com/. Accessed 16 Apr 2015.
40. Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2015;8(1):e001593.
41. Lange RA, Hillis LD. The duel between dual antiplatelet therapies. N Engl J Med. 2013;368(14):1356-7.
42. European Medicines Agency. Plavix (clopidogrel): EU summary of product characteristics. 2015. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000174/WC500042189.pdf. Accessed 29 June 2015.
43. European Medicines Agency. Kengrexal (cangrelor): EU public assessment report. 2015. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/003773/WC500188100.pdf. Accessed 15 June 2015.
44. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57.
45. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15.
46. European Medicines Agency. Brilique (ticagrelor): EU summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001241/WC500100494.pdf. Accessed 29 June 2015.
47. European Medicines Agency. Efient (prasugrel): EU summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000984/WC500021971.pdf. Accessed 29 June 2015.
48. Tamborini Permunian E, Riva N, Guasti L, et al. Cangrelor for the treatment of arterial thrombosis: Pharmacokinetics/pharmacodynamics and clinical data. Expert Opin Drug Metab Toxicol. 2015;11(4):625-37.
49. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265-74.
50. Firstenberg MS, Dyke CM, Angiolillo DJ, et al. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. Heart Surg Forum. 2013;16(2):61-70.
51. Food and Drug Administration. FDA briefing document for the cardiovascular and renal drugs advisory committee (CRDAC): cangrelor injection. 2014. http://www.fda.gov. Accessed 1 Apr 2015.
52. Food and Drug Administration. FDA briefing document for the cardiovascular and renal drugs advisory committee (CRDAC): Kengreal (cangrelor) for injection. 2015. http://www.fda.gov. Accessed 14 Apr 2015.